Square Pharmaceuticals PLC.

DSE:SQURPHARMA Stok Raporu

Piyasa değeri: ৳193.8b

Square Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Square Pharmaceuticals has been growing earnings at an average annual rate of 10.7%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 9.9% per year. Square Pharmaceuticals's return on equity is 16.6%, and it has net margins of 29.4%.

Anahtar bilgiler

10.7%

Kazanç büyüme oranı

10.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi11.0%
Gelir büyüme oranı9.9%
Özkaynak getirisi16.6%
Net Marj29.4%
Son Kazanç Güncellemesi31 Mar 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Square Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

DSE:SQURPHARMA Gelir, gider ve kazançlar (BDT Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 2468,81120,23815,6720
31 Dec 2367,46919,59914,7610
30 Sep 2365,13719,48014,1260
30 Jun 2362,74818,98013,5990
31 Mar 2362,02018,85613,7120
31 Dec 2260,78219,14313,0980
30 Sep 2258,79118,68012,5970
30 Jun 2257,59818,15712,1180
31 Mar 2256,71318,52611,1810
31 Dec 2154,83417,81910,8250
30 Sep 2153,00417,01210,4250
30 Jun 2150,70315,94710,0340
31 Mar 2149,02114,4849,4060
31 Dec 2048,39514,2379,2050
30 Sep 2047,15813,9339,0230
30 Jun 2045,87613,3548,8550
31 Mar 2046,36013,7338,7750
31 Dec 1945,13813,2368,4830
30 Sep 1944,78512,8318,2660
30 Jun 1944,03412,6468,0380
31 Mar 1942,32212,1687,4540
31 Dec 1841,25212,0257,4790
30 Sep 1840,32811,7547,2080
30 Jun 1839,65411,5946,9960
31 Mar 1839,47411,6676,8490
31 Dec 1739,13111,6226,4800
30 Sep 1737,97811,2226,3300
30 Jun 1736,54310,6376,1930
31 Mar 1735,58410,3306,1020
31 Dec 1634,5349,8935,4900
30 Sep 1633,4489,6395,3150
30 Jun 1633,0749,1995,3710
31 Dec 1529,6427,7704,9660
30 Sep 1528,4007,0914,7920
30 Jun 1527,5316,4114,7110
31 Mar 1525,9796,0325,0910
31 Dec 1425,8585,0604,6320
30 Sep 1425,5115,1224,4470
30 Jun 1424,1765,0024,3370
31 Mar 1423,2684,9454,1620
31 Dec 1323,0184,9884,2450

Kaliteli Kazançlar: SQURPHARMA has high quality earnings.

Büyüyen Kar Marjı: SQURPHARMA's current net profit margins (29.4%) are lower than last year (30.4%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SQURPHARMA's earnings have grown by 10.7% per year over the past 5 years.

Büyüme Hızlandırma: SQURPHARMA's earnings growth over the past year (7.3%) is below its 5-year average (10.7% per year).

Kazançlar vs. Sektör: SQURPHARMA earnings growth over the past year (7.3%) exceeded the Pharmaceuticals industry -2.8%.


Özkaynak Getirisi

Yüksek ROE: SQURPHARMA's Return on Equity (16.6%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin